Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 17/20 | 0.97 |
| ▸ | TUBB4A | P04350 | 7/20 | 0.97 |
| ▸ | TUBB | P07437 | 7/20 | 0.97 |
| ▸ | TUBA3C | P0DPH7 | 7/20 | 0.97 |
| ▸ | TUBA1B | P68363 | 7/20 | 0.97 |
| ▸ | TUBA4A | P68366 | 7/20 | 0.97 |
| ▸ | TUBB4B | P68371 | 7/20 | 0.97 |
| ▸ | TUBB3 | Q13509 | 7/20 | 0.97 |
| ▸ | TUBB2A | Q13885 | 7/20 | 0.97 |
| ▸ | TUBB8 | Q3ZCM7 | 7/20 | 0.97 |
| ▸ | TUBA3E | Q6PEY2 | 7/20 | 0.97 |
| ▸ | TUBA1A | Q71U36 | 7/20 | 0.97 |
| ▸ | TUBA1C | Q9BQE3 | 7/20 | 0.97 |
| ▸ | TUBB6 | Q9BUF5 | 7/20 | 0.97 |
| ▸ | TUBB2B | Q9BVA1 | 7/20 | 0.97 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.97 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.97 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.97 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.97 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E-Combretastatin A-4 SCHEMBL9707931 | 0.98 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin A4 SCHEMBL18945 | 0.98 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin A4 SCHEMBL29355902 | 0.98 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin A4 SCHEMBL18946 | 0.98 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin A4 SCHEMBL29501750 | 0.98 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin A4 SCHEMBL6456251 | 0.94 | TUBB1 (0.91) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13813246 | 0.93 | TUBB1 (0.90) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin A4 SCHEMBL5073658 | 0.92 | TUBB1 (0.88) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin A4 SCHEMBL8188814 | 0.91 | TUBB1 (0.85) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin A4 SCHEMBL6905413 | 0.90 | TUBB1 (0.83) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1351573-A4 | METHODS FOR MODULATING TUMOR GROWTH AND METASTASIS | BRISTOL MYERS SQUIBB CO (US) | 2007-03-28 | — | — | EP | claimed |
| EP-1351573-A1 | METHODS FOR MODULATING TUMOR GROWTH AND METASTASIS | Bristol-Myers Squibb Company (US) | 2003-10-15 | — | — | EP | claimed |
| WO-2002056692-A1 | METHODS FOR MODULATING TUMOR GROWTH AND METASTASIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-25 | — | — | WO | claimed |
| CN-101602778-A | CA-4 P and preparation method thereof and pharmaceutical composition | SOUTHWEST SYNTHETIC PHARMACEUT (CN) | 2009-12-16 | — | — | CN | disclosed |
| US-20090258937-A1 | Methods for Modulating Tumor Growth and Metastasis | BRISTOL MYERS SQUIBB COMPANY | 2009-10-15 | — | — | US | disclosed |
| EP-1351573-A4 | METHODS FOR MODULATING TUMOR GROWTH AND METASTASIS | BRISTOL MYERS SQUIBB CO (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060194770-A1 | Methods for modulating tumor growth and metastasis | OXIGENE, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20060100179-A1 | Compositions and methods for use in targeting vascular destruction | OXIGENE, INC. | 2006-05-11 | — | — | US | disclosed |
| US-7037906-B1 | Methods for modulating tumor growth and metastasis | OXIGENE, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-6956054-B2 | Compositions and methods for use in targeting vascular destruction | BAYLOR UNIVERSITY (US) | 2005-10-18 | — | — | US | disclosed |
| EP-1351573-A1 | METHODS FOR MODULATING TUMOR GROWTH AND METASTASIS | Bristol-Myers Squibb Company (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030109500-A1 | Compositions and methods for use in targeting vascular destruction | MATEON THERAPEUTICS, INC. | 2003-06-12 | — | — | US | disclosed |
| US-6538038-B1 | A method of treating a warm-blooded animal having a vascular proliferative disorder, comprising administering, to the animal, an amount of a prodrug of a tubulin binding agent, other than combretastatin A4 disodium phosphate to achieve | OXIGENE, INC. | 2003-03-25 | — | — | US | disclosed |
| WO-2002056692-A1 | METHODS FOR MODULATING TUMOR GROWTH AND METASTASIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194770-A1 | Methods for modulating tumor growth and metastasis | HGF, HDGF, MKI67 | TUBB1 46/4885TUBB4A 74/4885TUBB 106/4885 |
| US-20030109500-A1 | Compositions and methods for use in targeting vascular destruction | ALPP, MVD, TYMP | TUBB1 1065/4885TUBB4A 1193/4885TUBB 1273/4885 |
| US-20090258937-A1 | Methods for Modulating Tumor Growth and Metastasis | HGF, HDGF, MKI67 | TUBB1 46/4885TUBB4A 74/4885TUBB 106/4885 |
| US-20060100179-A1 | Compositions and methods for use in targeting vascular destruction | ALPP, MVD, TYMP | TUBB1 1065/4885TUBB4A 1193/4885TUBB 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.